Autres langues Toleranzia AB

Actions

Marché Fermé - Nasdaq Stockholm Autres places de cotation 15:11:35 14/05/2024			Varia. 5j.	Varia. 1 janv.
0,528 ^SEK	-1,49%		-2,22%	+23,36%

23/02	Toleranzia AB publie ses résultats pour le quatrième trimestre clos le 31 décembre 2023	CI
23/02	Toleranzia AB publie ses résultats pour l'exercice clos le 31 décembre 2023	CI

Toleranzia AB: Annual report for the financial year 2023	30/04
Toleranzia AB receives loan commitment of SEK 20 million	24/04
Toleranzia reports positive outcome from advisory meeting with the German Medicines Agency for the TOL2 development program	18/03
Toleranzia AB – Year-End Report 2023	23/02
Toleranzia AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	23/02
Toleranzia AB Reports Earnings Results for the Full Year Ended December 31, 2023	23/02
Toleranzia successfully completes GLP toxicology study of TOL2	15/01
Toleranzia AB Successfully Completes GLP Toxicology Study of TOL2	15/01
Toleranzia AB starts production of finished drug product for clinical studies	21/12
Toleranzia AB Starts Production of Completed Drug Product for Clinical Studies	21/12
Toleranzia AB presents Nomination Committee	15/12
Toleranzia AB Announces Nomination Committee	15/12
Toleranzia reports positive feedback from meeting with the Danish Medicines Agency	06/12
Toleranzia AB: Interim report third quarter 2023	27/10/23
Toleranzia AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	27/10/23
Toleranzia Appoints Successor to Outgoing CFO	16/10/23
Toleranzia appoints Thomas Pålsson as new Chief Financial Officer	16/10/23
Toleranzia AB Announces Executive Changes	16/10/23
Toleranzia starts toxicology study of its lead drug candidate TOL2	26/09/23
Toleranzia AB Starts Toxicology Study of its Lead Drug Candidate TOL2	26/09/23

Aucun résultat pour cette recherche